---
title: Antigen escape as a shared mechanism of resistance to BCMA-directed therapies
  in multiple myeloma
date: '2024-05-10'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38728378/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20240511181524&v=2.18.0.post9+e462414
source: Blood
description: B-cell maturation antigen (BCMA)-targeting therapeutics have dramatically
  improved outcomes in relapsed/refractory multiple myeloma (RRMM). However, whether
  the mechanisms of resistance between these therapies are shared and how the identification
  of such mechanisms before therapy initiation could refine clinical decision-making
  remains undefined. We analyzed outcomes for 72 RRMM patients treated with teclistamab,
  a CD3 x BCMA bispecific antibody (BsAb), 42% (30/72) of whom had ...
disable_comments: true
---
B-cell maturation antigen (BCMA)-targeting therapeutics have dramatically improved outcomes in relapsed/refractory multiple myeloma (RRMM). However, whether the mechanisms of resistance between these therapies are shared and how the identification of such mechanisms before therapy initiation could refine clinical decision-making remains undefined. We analyzed outcomes for 72 RRMM patients treated with teclistamab, a CD3 x BCMA bispecific antibody (BsAb), 42% (30/72) of whom had ...